Tharimmune, Inc. | WebDisclosure

PRESS RELEASE

published on 05/19/2025 at 14:01, 9 months 1 day ago

Tharimmune Appoints Renowned Counter-Terrorism and Critical Infrastructure Expert James Gordon Liddy (CDR US Navy SEAL (Ret)) as Key Strategic Advisor Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback
Tharimmune, Inc. appoints James Gordon Liddy as strategic advisor for TH104 development, targeting high-potency opioid exposure. FDA feedback positive for prophylaxis indication

Tharimmune Inc. FDA Feedback High-Potency Opioids James Gordon Liddy TH104 Development
BRIEF

published on 05/06/2025 at 14:06, 9 months 14 days ago

Tharimmune Reports Positive Phase 1 Results for TH104

Tharimmune Inc. FDA Feedback Phase 1 Study Opioid Prophylaxis TH104 Buccal Film
BRIEF

published on 05/06/2025 at 14:06, 9 months 14 days ago

Tharimmune annonce des résultats positifs de phase 1 pour le TH104

Tharimmune Inc. Étude De Phase 1 Commentaires De La FDA Prophylaxie Aux Opioïdes Film Buccal TH104
PRESS RELEASE

published on 05/06/2025 at 14:01, 9 months 14 days ago

Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback
Tharimmune, Inc. presents promising pharmacokinetic and metabolism data of TH104, a buccal film of nalmefene, for prophylaxis against opioid exposure. Study results showcased at Digestive Disease Week 2025

Tharimmune Inc. TH104 Buccal Film Pharmacokinetic Study Opioid Prophylaxis
BRIEF

published on 05/01/2025 at 14:06, 9 months 19 days ago

Le TH104 de Tharimmune sera présenté lors de conférences médicales importantes

Biopharmaceutique TH104 Tharimmune DDW 2025 EASL 2025
BRIEF

published on 05/01/2025 at 14:06, 9 months 19 days ago

Tharimmune's TH104 to Be Presented at Notable Medical Conferences

TH104 Biopharmaceutical Tharimmune DDW 2025 EASL 2025
PRESS RELEASE

published on 05/01/2025 at 14:01, 9 months 19 days ago

Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences
Tharimmune, Inc. announces presentation of clinical data on lead drug TH104 at DDW and EASL Annual Meetings in May 2025, addressing unmet medical needs in immunology & inflammation

Tharimmune Inc. TH104 Clinical Data Immunology Unmet Medical Needs
BRIEF

published on 04/30/2025 at 14:06, 9 months 20 days ago

Tharimmune élargit son conseil d'administration avec de nouvelles nominations

Stratégie De Croissance Biopharmaceutique Direction Nominations Au Conseil D'administration Tharimmune
BRIEF

published on 04/30/2025 at 14:06, 9 months 20 days ago

Tharimmune Expands Board with New Appointments

Growth Strategy Biopharmaceutical Leadership Board Appointments Tharimmune
PRESS RELEASE

published on 04/30/2025 at 14:01, 9 months 20 days ago

Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors
Tharimmune, Inc. appoints Clay Kahler and Gary Stetz to its Board of Directors, expanding to 9 members. Kahler brings life sciences expertise while Stetz contributes financial acumen

Board Of Directors Financial Expertise Tharimmune Clay Kahler Gary Stetz

Published on 02/20/2026 at 20:15, 1 hour 26 minutes ago

Lithium South Announces Results of its Annual and Special Meeting of Securityholders
Published on 02/20/2026 at 20:15, 1 hour 26 minutes ago

Verdera Energy Announces Closing of Qualifying Transaction
Published on 02/20/2026 at 18:30, 3 hours 11 minutes ago

Sparta Updates Delay in Filing Annual Financial Statements
Published on 02/20/2026 at 15:45, 5 hours 56 minutes ago

Revolve Announces Closing of Initial US$10 Million Advance on Strategic Financing With Callaway
Published on 02/20/2026 at 14:30, 7 hours 11 minutes ago

Norse Gold Announces Application for Reactivation to TSX-V, Private Placement Financing and Stock Options Grant

View all ACCESSWIRE

Published on 02/20/2026 at 18:36, 3 hours 5 minutes ago

EQS-Adhoc: innoscripta SE: Management Board Proposes Dividend of EUR 4.00 per Share
Published on 02/20/2026 at 18:31, 3 hours 10 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/20/2026 at 18:23, 3 hours 18 minutes ago

POS-Transaction in Own Shares
Published on 02/20/2026 at 18:00, 3 hours 41 minutes ago

Leclanché conclut un accord de financement d’un montant de CHF 16,7 millions pour soutenir ses opérations à court terme
Published on 02/20/2026 at 18:00, 3 hours 41 minutes ago

Leclanché Secures Financing Arrangement in the amount of CHF 16.7 million to Support Near-Term Operations

View all EQS

Published on 02/20/2026 at 19:29, 2 hours 12 minutes ago

SFPI GROUP: Liquidity agreement report S2 2025
Published on 02/20/2026 at 19:29, 2 hours 12 minutes ago

SFPI GROUP: bilan du contrat de liquidité S2 S025
Published on 02/20/2026 at 18:00, 3 hours 41 minutes ago

TERACT - Termination of liquidity agreement
Published on 02/20/2026 at 18:00, 3 hours 41 minutes ago

TERACT - Résiliation du contrat de liquidité
Published on 02/20/2026 at 17:35, 4 hours 6 minutes ago

CHIFFRE D'AFFAIRES 2025

View all LES ECHOS COMFI WIRE

News